Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI

Quest Diagnostics has announced a strategic acquisition of select assets from PathAI Diagnostics to enhance its AI and digital pathology capabilities, particularly in cancer diagnosis. This move, expected to close in Q2 2024, includes the transformation of PathAI’s Memphis lab into Quest’s AI and digital R&D center. Additionally, Quest will license PathAI's AISight™ system for improved pathology services across the U.S., aiming to boost efficiency and quality in disease diagnosis and treatment.